Ampio Pharmaceuticals (NYSE:AMPE) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Ampio Pharmaceuticals (NYSE:AMPEGet Free Report) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Ampio Pharmaceuticals Stock Performance

Ampio Pharmaceuticals stock opened at $0.21 on Friday. The company has a market capitalization of $239,400.00, a price-to-earnings ratio of -0.02 and a beta of 2.14. The company’s 50 day simple moving average is $0.52 and its 200-day simple moving average is $1.46. Ampio Pharmaceuticals has a 1 year low of $0.14 and a 1 year high of $8.30.

Ampio Pharmaceuticals (NYSE:AMPEGet Free Report) last posted its quarterly earnings data on Wednesday, March 27th. The company reported ($2.48) earnings per share (EPS) for the quarter.

About Ampio Pharmaceuticals

(Get Free Report)

Ampio Pharmaceuticals, Inc, a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Featured Articles

Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.